Welcome to our dedicated page for SRGA news (Ticker: SRGA), a resource for investors and traders seeking the latest updates and insights on SRGA stock.
Surgalign Holdings, Inc. (SRGA) delivers cutting-edge medical technologies that enhance surgical outcomes across orthopedics, spine care, and trauma procedures. This dedicated news hub provides investors and healthcare professionals with essential updates about the company’s advancements in surgical implant solutions.
Access authoritative information on SRGA’s financial performance, product innovations, and regulatory milestones. Track developments surrounding flagship technologies like the Coflex Interlaminar Stabilization Device and Simmetry Sacroiliac Joint Fusion System, which demonstrate the company’s commitment to reducing postoperative complications and improving patient recovery.
Our curated news collection features earnings announcements, partnership updates, and clinical study results – all vital for understanding SRGA’s market position. Discover how the company’s direct distribution network and TETRAfuse 3D technology continue shaping the future of spinal fusion procedures worldwide.
Bookmark this page for streamlined access to Surgalign Holdings’ official communications and third-party analyses. Stay informed about strategic initiatives from this Deerfield-based innovator through our continuously updated news repository.
Surgalign Holdings, Inc. (NASDAQ: SRGA) announced on April 10, 2023, that it received a notification from Nasdaq indicating it is no longer in compliance with the $10 million minimum stockholders’ equity requirement for continued listing. The notification does not immediately affect the trading of its common stock. The company has 45 days to submit a plan for compliance, which may include transferring its listing to the NASDAQ Capital Market. If accepted, Surgalign could be granted up to 180 days to demonstrate compliance. The company plans to submit this plan by May 25, 2023.
Surgalign focuses on digital health and innovative solutions for surgical care and operates in over 40 countries.
Surgalign Holdings, Inc. (NASDAQ: SRGA) reported Q4 and full-year 2022 results, highlighting a revenue decline to $20.6 million from $21.8 million year-over-year. GAAP gross margin was -13.6%, down from 56.5% in Q4 2021 due to inventory write-downs related to restructuring. Nonetheless, total operating expenses decreased significantly to $45.3 million from $105 million a year prior. The company successfully closed a $12 million offering and sold its Coflex product line for $17 million, boosting its cash position. Surgalign aims to achieve $30-$35 million in cash savings in 2023 and believes it can maintain liquidity through Q4 2023.
Surgalign Holdings, Inc. (NASDAQ: SRGA) announced plans to release its financial results for Q4 and full year 2022 after market close on March 30, 2023. A conference call will follow at 4:30 p.m. ET, accessible via phone or webcast. The company focuses on advancing digital health in the surgical landscape, with operations in the U.S. and approximately 50 countries. Surgalign aims to deliver superior clinical outcomes and has faced various forward-looking risks including financial stability, litigation, and integration challenges from recent acquisitions. Investor relations details are provided for further inquiries.
